{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:09:51Z","timestamp":1789150191669,"version":"build-2803163510"},"reference-count":38,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"unspecified","delay-in-days":72,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2026,8,29]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/Aims<\/jats:title>\n                    <jats:p>To determine whether first-year response to low-dose atropine predicts long-term myopia control and may guide treatment escalation in myopic children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective chart review (2012\u20132025) identified children treated with atropine 0.01%\u20130.05% at a single practice with \u226554 months of treatment. Children were excluded with insufficient follow-up (&lt;54 months of treatment), comorbidities that might affect myopia progression or concurrent baseline optical myopia-control therapy. First-year response was modelled as the spherical equivalent refraction (SER) progression rate (diopters (D)\/year, continuous, positive values indicating worsening myopia) and by responder status (defined as\u22640.25D total progression at 12\u00b13 months). The primary outcome was successful control maintaining\u22640.25 D\/year over follow-up. Key secondary outcomes were total SER progression and time-to-treatment escalation. Eye-level models accounted for correlation between fellow eyes and adjusted for baseline age and baseline SER.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>71 children (142 eyes) had a mean follow-up of 6.8\u00b12.0 years. First-year responders included 101\/142 eyes (71%) with higher odds of successful control (adjusted OR 2.66, 95%\u2009CI 1.11 to 6.35, p=0.028) and less total SER progression (adjusted difference 0.57D, 95%\u2009CI 0.28 to 0.86, p&lt;0.001). Each additional 0.25 D\/year of year-1 progression was associated with lower odds of successful control (OR 0.73, 95%\u2009CI 0.59 to 0.89, p=0.002) and greater total progression (0.22 D more, 95%\u2009CI 0.16 to 0.29, p&lt;0.001). Dose escalation occurred earlier in nonresponders; responders had a lower hazard of escalation (HR\u202f0.27, 95%\u202fCI\u202f0.14 to 0.52).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>First-year SER change is strongly predictive of long-term outcomes; despite earlier treatment escalation in nonresponders, responders had a much higher likelihood of sustained long-term control. Early response assessment may help identify high-risk patients for closer monitoring and\/or treatment intensification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2026-002759","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:35:22Z","timestamp":1789148122000},"page":"e002759","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive value of early treatment response for long-term outcomes after seven years on low-dose atropine"],"prefix":"10.1136","volume":"11","author":[{"given":"Karenna","family":"Mehta","sequence":"first","affiliation":[{"name":"South Bay Family Eye, Long Beach, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2422-0337","authenticated-orcid":false,"given":"Robert","family":"Clark","sequence":"additional","affiliation":[{"name":"South Bay Family Eye, Long Beach, California, USA"},{"name":"Department of Ophthalmology, University of California Los Angeles, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026091110351524000_11.3.e002759.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.006"},{"key":"2026091110351524000_11.3.e002759.2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2147\/OPTH.S164641","article-title":"Myopia prevalence and risk factors in children","volume":"12","author":"Theophanous","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"2026091110351524000_11.3.e002759.3","doi-asserted-by":"publisher","DOI":"10.3109\/09286589609071597"},{"key":"2026091110351524000_11.3.e002759.4","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.62.10.36","article-title":"Myopia Progression as a Function of Sex, Age, and Ethnicity","volume":"62","author":"Jones-Jordan","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2026091110351524000_11.3.e002759.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60272-4"},{"key":"2026091110351524000_11.3.e002759.6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/ICL.0000000000001017","article-title":"Long-Term Efficacy of Orthokeratology to Control Myopia Progression","volume":"49","author":"Lv","year":"2023","journal-title":"Eye Contact Lens"},{"key":"2026091110351524000_11.3.e002759.7","doi-asserted-by":"crossref","first-page":"102251","DOI":"10.1016\/j.clae.2024.102251","article-title":"A new look at the myopia control efficacy of orthokeratology","volume":"47","author":"Santodomingo-Rubido","year":"2024","journal-title":"Contact Lens and Anterior Eye"},{"key":"2026091110351524000_11.3.e002759.8","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000001410"},{"key":"2026091110351524000_11.3.e002759.9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.survophthal.2019.10.001","article-title":"Multifocal spectacles in childhood myopia: Are treatment effects maintained? A systematic review and meta-analysis","volume":"65","author":"Kaphle","year":"2020","journal-title":"Surv Ophthalmol"},{"key":"2026091110351524000_11.3.e002759.10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/jamaophthalmol.2023.5467","article-title":"Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term Assessment Study","volume":"142","author":"Li","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"2026091110351524000_11.3.e002759.11","first-page":"157","article-title":"Role of Atropine in the control of Myopia Progression- A Review","volume":"7","author":"Kaiti","year":"2022","journal-title":"Beyoglu Eye J"},{"key":"2026091110351524000_11.3.e002759.12","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000677"},{"key":"2026091110351524000_11.3.e002759.13","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis","volume":"135","author":"Gong","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"2026091110351524000_11.3.e002759.14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/ceo.14289","article-title":"Real-world outcomes of low-dose atropine therapy on myopia progression in an Australian cohort during the COVID-19 pandemic","volume":"51","author":"Usmani","year":"2023","journal-title":"Clin Exp Ophthalmol"},{"key":"2026091110351524000_11.3.e002759.15","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0043"},{"key":"2026091110351524000_11.3.e002759.16","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14148"},{"key":"2026091110351524000_11.3.e002759.17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial","volume":"141","author":"Repka","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"2026091110351524000_11.3.e002759.18","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","article-title":"Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial","volume":"141","author":"Zadnik","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"2026091110351524000_11.3.e002759.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.05.062"},{"key":"2026091110351524000_11.3.e002759.20","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ophtha.2024.03.013","article-title":"Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report","volume":"131","author":"Zhang","year":"2024","journal-title":"Ophthalmology"},{"key":"2026091110351524000_11.3.e002759.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.002"},{"key":"2026091110351524000_11.3.e002759.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.029"},{"key":"2026091110351524000_11.3.e002759.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.07.004"},{"key":"2026091110351524000_11.3.e002759.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.07.031"},{"key":"2026091110351524000_11.3.e002759.25","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and Efficacy of Low-Dose Atropine Eyedrops for the Treatment of Myopia Progression in Chinese Children: A Randomized Clinical Trial","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"2026091110351524000_11.3.e002759.26","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15761"},{"key":"2026091110351524000_11.3.e002759.27","article-title":"Interventions to slow progression of myopia in children","volume":"1","author":"Walline","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026091110351524000_11.3.e002759.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.11.010"},{"key":"2026091110351524000_11.3.e002759.29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-10978-3","article-title":"Characteristics of responders to atropine 0.01% as treatment in Asian myopic children","volume":"12","author":"Lee","year":"2022","journal-title":"Sci Rep"},{"key":"2026091110351524000_11.3.e002759.30","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ajo.2015.01.029","article-title":"Risk factors for progressive myopia in the atropine therapy for myopia study","volume":"159","author":"Loh","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"2026091110351524000_11.3.e002759.31","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25958"},{"key":"2026091110351524000_11.3.e002759.32","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/opo.13379","article-title":"Can we really distinguish \u201cresponders\u201d from \u201cnon-responders\u201d to myopia control interventions?","volume":"44","author":"Brennan","year":"2024","journal-title":"Ophthalmic Physiol Opt"},{"key":"2026091110351524000_11.3.e002759.33","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v015.i02"},{"key":"2026091110351524000_11.3.e002759.34","unstructured":"Team RC . R: A language and environment for statistical computing. R Foundation for Statistical Computing."},{"key":"2026091110351524000_11.3.e002759.35","doi-asserted-by":"crossref","unstructured":"Ho DE , Imai K , King G , et al . Nonparametric preprocessing for parametric causal inference. J Stat Softw 2011;42. doi:10.18637\/jss.v042.i08","DOI":"10.18637\/jss.v042.i08"},{"key":"2026091110351524000_11.3.e002759.36","doi-asserted-by":"crossref","unstructured":"Zeileis A , K\u00f6ll S , sandwich GN . Robust covariance matrix Estimators. J Stat Softw 2020;95.","DOI":"10.18637\/jss.v095.i01"},{"key":"2026091110351524000_11.3.e002759.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2006.00695.x"},{"key":"2026091110351524000_11.3.e002759.38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/ICL.0000000000000990","article-title":"Compounded 0.01% Atropine-What\u2019s in the Bottle?","volume":"49","author":"Richdale","year":"2023","journal-title":"Eye Contact Lens"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2026-002759","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:35:26Z","timestamp":1789148126000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2026-002759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,11]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjophth-2026-002759"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2026-002759","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}